{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "Not specified",
          "alt": "A30P",
          "position": "Not specified"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein is implicated in neurodegenerative diseases, including Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines a-synuclein's role in Parkinson’s disease and its functional implications."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro assays testing PLD2 inhibition were used to assess the functional impact of a-synuclein mutants.",
          "judgment": "Yes",
          "reasoning": "The assays directly test the functional impact on PLD2, which is relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls and replicates were not explicitly mentioned in the provided text.",
          "judgment": "No",
          "reasoning": "Insufficient information to confirm basic controls and replicates."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The functional impact of A30P on PLD2 inhibition is not explicitly detailed in the provided text.",
          "judgment": "No",
          "reasoning": "Insufficient data for statistical analysis or OddsPath calculation."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "Not specified",
          "alt": "A53T",
          "position": "Not specified"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein is implicated in neurodegenerative diseases, including Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines a-synuclein's role in Parkinson’s disease and its functional implications."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro assays testing PLD2 inhibition were used to assess the functional impact of a-synuclein mutants.",
          "judgment": "Yes",
          "reasoning": "The assays directly test the functional impact on PLD2, which is relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls and replicates were not explicitly mentioned in the provided text.",
          "judgment": "No",
          "reasoning": "Insufficient information to confirm basic controls and replicates."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The functional impact of A53T on PLD2 inhibition is not explicitly detailed in the provided text.",
          "judgment": "No",
          "reasoning": "Insufficient data for statistical analysis or OddsPath calculation."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    }
  ]
}